Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more ...

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...

The American Medical Association (AMA) has announced a new category III CPT code for the use of Avvio Medical’s Enhanced Lithotripsy System (ELS) for acoustic enhancer microbubble cavitation (AEMC) ...

In this video, Bridget Lang Findlay, MD, a reconstructive urologist with Mayo Clinic in Phoenix, Arizona, focuses on her study examining long-term bladder management strategies among women with spinal ...

Data showed that African American men faced significant delays in treatment initiation. A recent analysis demonstrated that although African American men and non-African American men had comparable ...

The FDA and the French National Agency for the Safety of Medicines and Health Products (ANSM) have granted an investigational device exemption (IDE) clearance to a pivotal trial of the UroActive smart ...

Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...

Vikram M. Narayan, MD, discusses Emory's recent shift to Apple products, aimed at reducing physician burnout and improving patient interactions.

In this landmark episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with one of the world’s foremost experts in sexual medicine, John P. Mulhall, MD, of Memorial Sloan Kettering Cancer ...

A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

Key Takeaways Hamlet BioPharma is preparing to initiate a phase 3 trial of Alpha1H for NMIBC, following a successful FDA meeting. Alpha1H received fast track designation, allowing for accelerated ...

Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and ...